TNF and demyelinating disease: Despite this dichotomy, current anti-TNF therapies indiscriminately neutralize TNF itself — suppressing both beneficial and detrimental signaling arms — which has led to well-documented adverse effects including increased risk of infection, demyelinating disease, and impaired tissue repair41–43.